NMDA receptors and schizophrenia

Current Opinion in Pharmacology

Volumn 7, Issue 1, 2007, Pages 48-55

  Kristiansen, Lars V ^a   Huerta, Ibone ^a   Beneyto, Monica ^a   Meador Woodruff, James H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CLOZAPINE; DIZOCILPINE; GLUTAMIC ACID; GUANYLATE KINASE; HALOPERIDOL; INTERMEDIATE FILAMENT PROTEIN; KETAMINE; MESSENGER RNA; MYOSIN LIGHT CHAIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; SARCOSINE; SULPIRIDE;

AUTOPSY; BASAL GANGLION; BRAIN CORTEX; BRAIN REGION; CELL FUNCTION; HIPPOCAMPUS; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC TRANSMISSION; THALAMUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 33846981870     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.08.013     Document Type: Review

References (83)

1. Tamminga C.A., and Holcomb H.H. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 10 (2005) 27-39. This is a thorough review of the clinical features and molecular pathophysiology of schizophrenia.
2. Shih R.A., Belmonte P.L., and Zandi P.P. A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. Int Rev Psychiatry 16 (2004) 260-283
3. Muntaner C., Eaton W.W., Miech R., and O'Campo P. Socioeconomic position and major mental disorders. Epidemiol Rev 26 (2004) 53-62
4. Lyne J., Kelly B.D., and O'Connor W.T. Schizophrenia: a review of neuropharmacology. Ir J Med Sci 173 (2004) 155-159
5. Belsham B. Glutamate and its role in psychiatric illness. Hum Psychopharmacol 16 (2001) 139-146
6. Tekin S., and Cummings J.L. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 53 (2002) 647-654
7. Lewis D.A., Glantz L.A., Pierri J.N., and Sweet R.A. Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons. Ann N Y Acad Sci 1003 (2003) 102-112
8. Simeone T.A., Sanchez R.M., and Rho J.M. Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J Child Neurol 19 (2004) 343-360 discussion 361
9. Stephenson F.A. Subunit characterization of NMDA receptors. Curr Drug Targets 2 (2001) 233-239
10. Lynch D.R., and Guttmann R.P. NMDA receptor pharmacology: perspectives from molecular biology. Curr Drug Targets 2 (2001) 215-231
11. Goebel D.J., and Poosch M.S. NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A. Brain Res Mol Brain Res 69 (1999) 164-170
12. Cull-Candy S., Brickley S., and Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11 (2001) 327-335
13. Matsuda K., Fletcher M., Kamiya Y., and Yuzaki M. Specific assembly with the NMDA receptor 3B subunit controls surface expression and calcium permeability of NMDA receptors. J Neurosci 23 (2003) 10064-10073
14. Llansola M., Sanchez-Perez A., Cauli O., and Felipo V. Modulation of NMDA receptors in the cerebellum. 1. Properties of the NMDA receptor that modulate its function. Cerebellum 4 (2005) 154-161
15. Chung H.J., Huang Y.H., Lau L.F., and Huganir R.L. Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand. J Neurosci 24 (2004) 10248-10259
16. Panatier A., Theodosis D.T., Mothet J.P., Touquet B., Pollegioni L., Poulain D.A., and Oliet S.H. Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell 125 (2006) 775-784. This paper demonstrates that astrocytic D-serine, not glycine, is the primary ligand for the glycine modulatory site in the NMDA receptor.
17. Rachline J., Perin-Dureau F., Le Goff A., Neyton J., and Paoletti P. The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J Neurosci 25 (2005) 308-317
18. Jang M.K., Mierke D.F., Russek S.J., and Farb D.H. A steroid modulatory domain on NR2B controls N-methyl-d-aspartate receptor proton sensitivity. Proc Natl Acad Sci USA 101 (2004) 8198-8203
19. Traynelis S.F., Burgess M.F., Zheng F., Lyuboslavsky P., and Powers J.L. Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci 18 (1998) 6163-6175
20. Yamakura T., and Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol 59 (1999) 279-298
21. Huggins D.J., and Grant G.H. The function of the amino terminal domain in NMDA receptor modulation. J Mol Graph Model 23 (2005) 381-388
22. Conti F., Barbaresi P., Melone M., and Ducati A. Neuronal and glial localization of NR1 and NR2A/B subunits of the NMDA receptor in the human cerebral cortex. Cereb Cortex 9 (1999) 110-120
23. Standaert D.G., Friberg I.K., Landwehrmeyer G.B., Young A.B., and Penney Jr. J.B. Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. Brain Res Mol Brain Res 64 (1999) 11-23
24. Ehlers M.D., Fung E.T., O'Brien R.J., and Huganir R.L. Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J Neurosci 18 (1998) 720-730
25. Amparan D., Avram D., Thomas C.G., Lindahl M.G., Yang J., Bajaj G., and Ishmael J.E. Direct interaction of myosin regulatory light chain with the NMDA receptor. J Neurochem 92 (2005) 349-361
26. Wyszynski M., Lin J., Rao A., Nigh E., Beggs A.H., Craig A.M., and Sheng M. Competitive binding of alpha-actinin and calmodulin to the NMDA receptor. Nature 385 (1997) 439-442
27. Collins M.O., Husi H., Yu L., Brandon J.M., Anderson C.N., Blackstock W.P., Choudhary J.S., and Grant S.G. Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J Neurochem 97 Suppl 1 (2006) 16-23. Proteomic analysis of NR1/NR2-associated PSD complexes from the mouse central nervous system.
28. Nakagawa T., Engler J.A., and Sheng M. The dynamic turnover and functional roles of alpha-actinin in dendritic spines. Neuropharmacology 47 (2004) 734-745
29. Ratnam J., and Teichberg V.I. Neurofilament-light increases the cell surface expression of the N-methyl-D-aspartate receptor and prevents its ubiquitination. J Neurochem 92 (2005) 878-885
30. Aoki C., Miko I., Oviedo H., Mikeladze-Dvali T., Alexandre L., Sweeney N., and Bredt D.S. Electron microscopic immunocytochemical detection of PSD-95, PSD-93, SAP-102, and SAP-97 at postsynaptic, presynaptic, and nonsynaptic sites of adult and neonatal rat visual cortex. Synapse 40 (2001) 239-257
31. van Zundert B., Yoshii A., and Constantine-Paton M. Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal. Trends Neurosci 27 (2004) 428-437
32. Tao Y.X., Rumbaugh G., Wang G.D., Petralia R.S., Zhao C., Kauer F.W., Tao F., Zhuo M., Wenthold R.J., Raja S.N., et al. Impaired NMDA receptor-mediated postsynaptic function and blunted NMDA receptor-dependent persistent pain in mice lacking postsynaptic density-93 protein. J Neurosci 23 (2003) 6703-6712
33. Tu J.C., Xiao B., Naisbitt S., Yuan J.P., Petralia R.S., Brakeman P., Doan A., Aakalu V.K., Lanahan A.A., Sheng M., et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23 (1999) 583-592
34. Inamura M., Itakura M., Okamoto H., Hoka S., Mizoguchi A., Fukazawa Y., Shigemoto R., Yamamori S., and Takahashi M. Differential localization and regulation of stargazin-like protein, gamma-8 and stargazin in the plasma membrane of hippocampal and cortical neurons. Neurosci Res 55 (2006) 45-53
35. Lindemeyer K., Leemhuis J., Loffler S., Grass N., Norenberg W., and Meyer D.K. Metabotropic glutamate receptors modulate the NMDA- and AMPA-induced gene expression in neocortical interneurons. Cereb Cortex 16 (2006) 1662-1677
36. Tigaret C.M., Thalhammer A., Rast G.F., Specht C.G., Auberson Y.P., Stewart M.G., and Schoepfer R. Subunit dependencies of N-methyl-D-aspartate (NMDA) receptor-induced alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor internalization. Mol Pharmacol 69 (2006) 1251-1259. This paper demonstrates subtype-dependent functional interactions between NMDA and AMPA receptors.
37. Moult P.R., Gladding C.M., Sanderson T.M., Fitzjohn S.M., Bashir Z.I., Molnar E., and Collingridge G.L. Tyrosine phosphatases regulate AMPA receptor trafficking during metabotropic glutamate receptor-mediated long-term depression. J Neurosci 26 (2006) 2544-2554
38. Mangiavacchi S., and Wolf M.E. Stimulation of N-methyl-D-aspartate receptors, AMPA receptors or metabotropic glutamate receptors leads to rapid internalization of AMPA receptors in cultured nucleus accumbens neurons. Eur J Neurosci 20 (2004) 649-657
39. Guillaud L., Setou M., and Hirokawa N. KIF17 dynamics and regulation of NR2B trafficking in hippocampal neurons. J Neurosci 23 (2003) 131-140
40. Setou M., Nakagawa T., Seog D.H., and Hirokawa N. Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport. Science 288 (2000) 1796-1802
41. Sans N., Prybylowski K., Petralia R.S., Chang K., Wang Y.X., Racca C., Vicini S., and Wenthold R.J. NMDA receptor trafficking through an interaction between PDZ proteins and the exocyst complex. Nat Cell Biol 5 (2003) 520-530
42. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney Jr. W.E., and Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16 (1996) 19-30
43. Dracheva S., Marras S.A., Elhakem S.L., Kramer F.R., Davis K.L., and Haroutunian V. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158 (2001) 1400-1410
44. Le Corre S., Harper C.G., Lopez P., Ward P., and Catts S. Increased levels of expression of an NMDARI splice variant in the superior temporal gyrus in schizophrenia. Neuroreport 11 (2000) 983-986
45. Sokolov B.P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J Neurochem 71 (1998) 2454-2464
46. Humphries C., Mortimer A., Hirsch S., and de Belleroche J. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 7 (1996) 2051-2055
47. Mueller H.T., and Meador-Woodruff J.H. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr Res 71 (2004) 361-370
48. Toro C., and Deakin J.F. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 80 (2005) 323-330
49. Kristiansen L.V., Beneyto M., Haroutunian V., and Meador-Woodruff J.H. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 11 (2006) 737-747. This paper reported alterations in the expression of NMDA receptor subunits and related PSD proteins in the cortex in schizophrenia by both in situ hybridization and Western blot analysis.
50. Nudmamud-Thanoi S., and Reynolds G.P. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett 372 (2004) 173-177
51. Okabe S., Miwa A., and Okado H. Alternative splicing of the C-terminal domain regulates cell surface expression of the NMDA receptor NR1 subunit. J Neurosci 19 (1999) 7781-7792
52. Pauly T., Schlicksupp A., Neugebauer R., and Kuhse J. Synaptic targeting of N-methyl-D-aspartate receptor splice variants is regulated differentially by receptor activity. Neuroscience 131 (2005) 99-111
53. Zavitsanou K., Ward P.B., and Huang X.F. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 27 (2002) 826-833
54. Kornhuber J., Mack-Burkhardt F., Riederer P., Hebenstreit G.F., Reynolds G.P., Andrews H.B., and Beckmann H. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77 (1989) 231-236
55. Noga J.T., Hyde T.M., Bachus S.E., Herman M.M., and Kleinman J.E. AMPA receptor binding in the dorsolateral prefrontal cortex of schizophrenics and controls. Schizophr Res 48 (2001) 361-363
56. Weissman A.D., Casanova M.F., Kleinman J.E., London E.D., and De Souza E.B. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 29 (1991) 41-54
57. Simpson M.D., Slater P., Royston M.C., and Deakin J.F. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res 6 (1991) 41-48
58. Grimwood S., Slater P., Deakin J.F., and Hutson P.H. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. Neuroreport 10 (1999) 461-465
59. Ohnuma T., Kato H., Arai H., Faull R.L., McKenna P.J., and Emson P.C. Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 11 (2000) 3133-3137
60. Toyooka K., Iritani S., Makifuchi T., Shirakawa O., Kitamura N., Maeda K., Nakamura R., Niizato K., Watanabe M., Kakita A., et al. Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J Neurochem 83 (2002) 797-806
61. McCullumsmith R, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 2006, in press.
62. Law A.J., and Deakin J.F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12 (2001) 2971-2974
63. Gao X.M., Sakai K., Roberts R.C., Conley R.R., Dean B., and Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157 (2000) 1141-1149
64. Popken G.J., Leggio M.G., Bunney W.E., and Jones E.G. Expression of mRNAs related to the GABAergic and glutamatergic neurotransmitter systems in the human thalamus: normal and schizophrenic. Thalamus and Related Systems 1 (2002) 349-369
65. Clinton S.M., and Meador-Woodruff J.H. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 29 (2004) 1353-1362
66. Ibrahim H.M., Hogg Jr. A.J., Healy D.J., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 157 (2000) 1811-1823
67. Clinton S.M., Haroutunian V., and Meador-Woodruff J.H. Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia. J Neurochem 98 (2006) 1114-1125. First study showing abnormalities in protein level expression of NMDA-interacting molecules in the thalamus in schizophrenia.
68. Clinton S.M., Abelson S., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Neurofilament subunit protein abnormalities in the thalamus in shizophrenia. Thalamus and Related Systems 2 (2004) 265-272
69. Clinton S.M., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry 160 (2003) 1100-1109
70. Meador-Woodruff J.H., Hogg Jr. A.J., and Smith R.E. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 55 (2001) 631-640
71. Aparicio-Legarza M.I., Davis B., Hutson P.H., and Reynolds G.P. Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci Lett 241 (1998) 143-146
72. Mueller H.T., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res Mol Brain Res 121 (2004) 60-69
73. Kristiansen L.V., and Meador-Woodruff J.H. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 78 (2005) 87-93
74. Kajimoto Y., Shirakawa O., Lin X.H., Hashimoto T., Kitamura N., Murakami N., Takumi T., and Maeda K. Synapse-associated protein 90/postsynaptic density-95-associated protein (SAPAP) is expressed differentially in phencyclidine-treated rats and is increased in the nucleus accumbens of patients with schizophrenia. Neuropsychopharmacology 28 (2003) 1831-1839
75. Toyoda H., Takahata R., Inayama Y., Sakai J., Matsumura H., Yoneda H., Asaba H., and Sakai T. Effect of antipsychotic drugs on the gene expression of NMDA receptor subunits in rats. Neurochem Res 22 (1997) 249-252
76. Riva M.A., Tascedda F., Lovati E., and Racagni G. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res 50 (1997) 136-142
77. Hanaoka T., Toyoda H., Mizuno T., Kikuyama H., Morimoto K., Takahata R., Matsumura H., and Yoneda H. Alterations in NMDA receptor subunit levels in the brain regions of rats chronically administered typical or atypical antipsychotic drugs. Neurochem Res 28 (2003) 919-924
78. Schmitt A., Zink M., Muller B., May B., Herb A., Jatzko A., Braus D.F., and Henn F.A. Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem Res 28 (2003) 235-241
79. Westhoff J.H., Hwang S.Y., Scott Duncan R., Ozawa F., Volpe P., Inokuchi K., and Koulen P. Vesl/Homer proteins regulate ryanodine receptor type 2 function and intracellular calcium signaling. Cell Calcium 34 (2003) 261-269
80. Tsai G.E., Yang P., Chang Y.C., and Chong M.Y. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 59 (2006) 230-234
81. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., and Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57 (2005) 577-585
82. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., and Tsai G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 62 (2005) 1196-1204
83. Steffek A.E., Haroutunian V., and Meador-Woodruff J.H. Serine racemase protein expression in cortex and hippocampus in schizophrenia. Neuroreport 17 (2006) 1181-1185